skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Cancer chemotherapy: targeting folic acid synthesis

Review

(3057) Views  (1510) Full article downloads

Authors: Nicole Hagner, Markus Joerger

Published Date November 2010 Volume 2010:2 Pages 293 - 301
DOI: http://dx.doi.org/10.2147/CMAR.S10043

Nicole Hagner, Markus Joerger
Department of Medical Oncology, Cantonal Hospital, St Gallen, Switzerland

Abstract: Antifolates are structural analogs of folates, essential one-carbon donors in the synthesis of DNA in mammalian cells. Antifolates are inhibitors of key enzymes in folate metabolism, namely dihydrofolate reductase, β-glycinamide ribonucleotide transformylase, 5'-amino-4'-imidazolecarboxamide ribonucleotide transformylase, and thymidylate synthetase. Methotrexate is one of the earliest anticancer drugs and is extensively used in lymphoma, acute lymphoblastic leukemia, and osteosarcoma, among others. Pemetrexed has been approved in combination with cisplatin as first-line treatment for advanced non-squamous-cell lung cancer, as a single agent for relapsed non-small-cell lung cancer after platinum-containing chemotherapy, and in combination with cisplatin for the treatment of pleural mesothelioma. Raltitrexed is approved in many countries (except in the United States) for advanced colorectal cancer, but its utilization is mainly limited to patients intolerant to 5-fluorouracil. Pralatrexate has recently been approved in the United States for relapsed or refractory peripheral T-cell lymphoma. This article gives an overview of the cellular mechanism, pharmacology, and clinical use of classical and newer antifolates and discusses some of the main resistance mechanisms to antifolate drugs.

Keywords: antifolates, cancer, molecular pharmacology, pemetrexed, methotrexate, folate metabolism






Readers of this article also read:

Topotecan in the treatment of relapsed small cell lung cancer
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Review of catumaxomab in the treatment of malignant ascites
Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario
A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University